5-Hydroxytryptamine and 5-Hydroxytryptamine-3 Receptor Antagonists
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 26 (sup188) , 92-100
- https://doi.org/10.3109/00365529109111236
Abstract
5-Hydroxytryptamine (5-HT) is present throughout the gastrointestinal tract, which acts as the major reservoir of this substance in the body. Its physiologic role has not been clearly established, although it seems likely that 5-HT is involved in the regulation of aspects of intestinal motility such as peristalsis and the migrating motor complex. In disease states the contribution of 5-HT is perhaps more clearly established, particularly its role in chemotherapy-induced emesis, in the carcinoid syndrome, and, possibly, in mediating the effect of some intestinal secretagogues, notably cholera toxin. Many of the functions of 5-HT in the gut have been elucidated as a result of the development of antagonists to 5-HT receptors. However, some of these compounds have 5-HT agonist activity as well as 5-HT receptor blocking activity, making interpretation of their effects in health and disease difficult. Nevertheless, 5-HT receptor antagonists are finding an important place in the management of the carcinoid syndrome and in chemotherapy-induced emesis and may well evolve as important agents for modulating gut motility and for inhibiting secretory states in the small and large intestine. The suggestion that 5-HT3 receptor antagonists might also modulate visceral sensation in the gut is of great interest because of their potential to relieve symptoms of functional bowel disorders such as pain, urgency, and bowel frequency.Keywords
This publication has 34 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Atracurium in Infants and ChildrenAnesthesiology, 1990
- Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5‐hydroxytryptamine receptor (type 3) antagonistAlimentary Pharmacology & Therapeutics, 1990
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- Prostaglandin E2 is a mediator of 5-hydroxytryptamine induced water and electrolyte secretion in the human jejunum.Gut, 1988
- Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist.BMJ, 1987
- Intraluminal release of serotonin, substance P, and gastrin in the canine small intestineDigestive Diseases and Sciences, 1987
- Inositol trisphosphate, a novel second messenger in cellular signal transductionNature, 1984
- 5-Hydroxytryptamine and cholera secretion: a histochemical and physiological study in cats.Gut, 1983
- Serotonin: Synthesis and Release from the Myenteric Plexus of the Mouse IntestineScience, 1965